Project description DEENESFRITPL Novel point-of-care cystic fibrosis monitoring test Chronic respiratory diseases are on the rise and becoming the third leading cause of mortality worldwide. French Rheonova is developing user-friendly monitoring based on the rheology of lung secretions. The focus of the EU-funded RheoCare project will be on cystic fibrosis as it already has organised care structures in Europe. The project's goal is to provide a dedicated plug-and-play rheometer with quantitative biomarkers and a high specificity, allowing a monitoring test within 10 minutes. Phase 1 clinical trials have demonstrated the reproducibility and the specificity of the biomarkers. The phase 2 clinical protocols are proceeding in order to demonstrate the medical benefit for patients. In addition, the company is working to develop an automated sample manipulation device that is currently at the stage of a feasibility study. Show the project objective Hide the project objective Objective Chronic respiratory diseases are expected to become the third cause of mortality worldwide by 2020. Patients experience periodic acute exacerbation phases favouring infections of the lower airways and causing irreversible loss of pulmonary capacity. These crises cannot be forecast with current techniques and require emergency hospitalisations, leading to healthcare costs (€24k per crisis) and antibioresistances due to wide-spectrum treatments. Among respiratory diseases, we choose to target cystic fibrosis (CF) in Europe as organised care structures pre-exist. CF also represents a very attractive market segment of $4.5B across the Group of Eight (G8).Rheonova develops a unique monitoring test based on the rheology of lung secretions (mucus). The RheoCare project will provide a dedicated plug-and-play rheometer, with a quantitative biomarker and a specificity above 80%, allowing a point-of-care CF monitoring test within 10 minutes as a first step towards personalised healthcare.Our four-patent-protected technique already assesses treatments efficiency and is commercialised to researchers. Phase 1 clinical trials have demonstrated the reproducibility and the robustness of our biomarkers. Two new clinical protocols (Phase 2) proceed in order to demonstrate the medical benefit for the patient, i.e. the reduction of hospitalisations by predicting the exacerbation phases and assessing treatment performance quantitatively. Within three years, Phase 3 clinical trials will support the commercialisation of the device in EU and China. We will address the medical market with an attractively-priced machine accompanied with specific consumables needed to test mucus samples.To support our ambition, we need to implement an automated sample manipulation device. Three priority tasks remain to complete the feasibility study: (i) remoulding the software, (ii) supporting our commercialisation plan, and (iii) defining the IP strategy regarding this new building block. Fields of science natural sciencescomputer and information sciencessoftwaresocial sciencessociologydemographymortalitymedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator RHEONOVA SAS Net EU contribution € 50 000,00 Address 31 BOULEVARD AGUTTE SEMBAT 38000 GRENOBLE France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Auvergne-Rhône-Alpes Rhône-Alpes Isère Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
